Background
Introduction
In industrialized countries the prognosis of HIV infection has improved considerably since highly active antiretroviral therapy (ART) was introduced from 1995 onwards , , . In low-income countries with a high burden of HIV and AIDS, ART has become more [1 2 3 ] widely available in recent years. The World Health Organisation (WHO) estimates that about 3 million people were receiving ART in lowand middle-income countries end of 2007, a 7.5-fold increase during the past four years . With increasing exposure to ART, the risk of [4 ] resistance and subsequent treatment failure has become more important, and switching of patients to alternative, second-line regimens is increasingly needed.
Whereas HIV-1 RNA concentration (viral load) is regularly assessed to diagnose treatment failure in high-income countries , viral [5 ] load measurements are often not available, or only available at high cost, in resource-constrained settings. Costs of second-line drugs are also high . The lack of viral load monitoring in resource-limited settings may lead to late switching of regimens, increase the risk of [6 ] viral resistance and jeopardize long-term prognosis: second-line regimens are the last treatment option for many patients in these settings.
Conversely, if treatment is switched unnecessarily, resources may be wasted and future treatment options reduced. Switching to second-line regimens is less common in lower-income settings compared to high-income countries , but direct comparisons of [7 8 ] switching rates between treatment programmes with and without access to viral load monitoring in resource-limited settings are lacking at present. 2 9 We studied rates of switching to second-line regimens, time to switching and determinants of switching in a collaborative network of treatment programmes in Africa, Asia and Latin America that includes both programmes that routinely monitor viral load, and programmes without access to viral load monitoring.
Methods The ART-LINC collaboration
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) collaboration of the International epidemiological Databases to Evaluate Aids (IeDEA) is a collaborative network of ART programmes, which has been described in detail elsewhere , . Briefly, [9 10 ] programmes from resource-constrained settings that collect data on patient characteristics and treatment outcomes were eligible for participation in ART-LINC. In all sites institutional review boards approved the participation in ART-LINC.
Inclusion criteria and definitions
We included all patients aged 16 years and older with known date of starting ART, who had not previously received ART, started ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen and had at least 6 months of follow-up. A switch to a second-line regimen was defined as a change from the initial NNRTI-based regimen to a protease inhibitor (PI)-based regimen after at least six months of follow-up, since WHO recommends switching due to treatment failure not before completion of at least 6 months of therapy . In addition at least one NRTI had to be changed. A patient was considered lost to follow up if the time between the last visit [11 ] and the closing date of the cohort was longer than one year.
Stage of disease was defined as less advanced (CDC stage A/B or WHO stage I/II) or advanced (CDC stage C or WHO stage III/IV). Routine viral load monitoring was defined as at least one viral load measurement between 3 and 9 months after starting ART in at least 50 of patients treated at that site. Measurements of CD4 and RNA values closest to the starting date of ART (within 6 months before up to % one week after the date of starting ART) were taken as the baseline levels. For CD4 counts below 25 cells/ l and HIV viral loads above μ 100,000 copies/ml the time window was extended to one year before starting therapy. At switching the time window was 3 months before up to 2 weeks after switching.
In patients who switched to a second-line regimen we determined whether immunological or virological failure had occurred during the 3 months before switching and examined the reasons for switching recorded in the database. Following WHO criteria we defined [11 ] immunological failure as a decline in the CD4 cell count to the baseline value or below, a decline of at least 50 from the highest count on % treatment or a persistent CD4 cell count below 100 cells/ l after six months of antiretroviral therapy. Virological failure was defined as a μ plasma HIV viral load value above 10,000 copies/ml .
[11 ]
Statistical analysis
Patient characteristics at start of first and second-line ART was compared between sites with and without viral load monitoring using chi-squared tests and Wilcoxon ranksum tests. We calculated times to switching and rates of switching per 100 person-years, and fitted random-effects Weibull models, comparing sites with and without routine viral load monitoring. We plotted Kaplan-Meier curves of the probability of switching to second-line ART therapy and obtained p values from log rank tests comparing programmes with and without virological monitoring. We measured time from 6 months after start of ART (baseline) to the time of switching, the time of the last follow-up visit, or three years after baseline, whichever came first. and without access to viral load monitoring and used tests of interaction to determine whether programmes differed.
We compared CD4 cell counts at the time of switching in sites with and without routine viral load monitoring and used linear regression analysis to examine whether differences persisted when adjusting for age, sex, clinical stage and CD4 cell count at baseline. The square-root of CD4 cell counts was used in these analyses. In sensitivity analyses we restricted data to sites from sub-Saharan Africa. All analyses were performed using Stata version 10 (Stata Corporation, College Station, Texas, USA). Results are presented as hazard ratios (HRs) with 95 confidence intervals (CIs) or medians with interquartile range (IQR).
%

Results
Sites and study populations
Seventeen treatment programmes from 14 countries were included ( ). All sites carried out routine CD4 monitoring and had Table 1 access to second-line therapy, 10 sites routinely monitored viral load. The database included 34,715 adult patients of whom 14,602 patients (42.1 ) were excluded for the following reasons: 1,403 (4.0 ) died before 6 months, 11,250 (32.4 ) had less than 6 months of follow-up
and 1,949 (5.6 ) started with a non-NNRTI-based ART. A total of 20,113 patients, including 6,369 patients (31.7 ) from programmes % % with routine viral load monitoring, and 16,591 (82.5 ) patients from sub-Saharan Africa, were analysed. A viral load value at 6 months % after ART initiation was available in 58 to 99 of patients at sites with routine viral load testing, and 0 to 7 at the other sites ( % % % % Table 1 ).
shows patient characteristics separately for programmes with and without viral load monitoring. The characteristics of patients Table 2 at start of ART were similar with respect to age, and sex, but median CD4 cell counts at the start of ART were lower in programmes with viral load monitoring compared to programmes without viral load monitoring (97 cells cells/ l versus 129 cells/ l, p<0.001). Both in sites μ μ with and without viral load monitoring the four most common initial regimens were lamivudine (3TC) with stavudine (d4T) or zidovudine (ZDV), combined with efavirenz (EFV) or nevirapine (NVP) ( ). Table 2 Rates and time to switching A total of 576 patients (2.9 ) switched to a second-line regimen. The rate of switching overall was 2.4 per 100 person-years (95 CI % % 2.2 2.6). It was higher in programmes with than in programs without access to viral load monitoring: 3.2 (95 CI 2.8 3.6) compared to 
Predictors and reasons of switching
The baseline CD4 cell count, but not clinical stage, was associated with switching both in sites with and without viral load monitoring:
the lower the CD4 cell count, the higher the probability of switching to a second-line regimen ( ). Switching was more frequent in Table 3 earlier calendar periods.
Reasons for switching were available for 241 (42 ) of the 576 patients who switched. Reasons were treatment failure (179 patients; 
Discussion
Many ART programmes in resource-limited settings do not have access to viral load testing to monitor treatment response, identify treatment failure and inform decisions on when to switch to a second-line regimen, but rely on clinical examinations and, where available, on CD4 cell counts. In this study of ART programmes from sub-Saharan Africa, Asia and Latin America all sites had access to CD4 cell counts and some had access to viral load monitoring. We could thus study patterns of switching to second-line regimens in sites with and 4 9 without
Our study included over 20,000 patients who started ART and almost 600 patients who switched to second-line ART. The decision to measure, or not to measure, viral load in an individual patient will often be related to prognosis and the probability of switching to a second line regimen. By comparing sites with and without a policy of monitoring viral load, rather than comparing patients with and without available viral load measurements, such confounding by the indication to test was avoided. The definition we used for second-line ART is in accordance with WHO recommendations and was used in a previous analysis of the M decins Sans Fronti res (MSF) [11 ] é è programmes in Africa, Asia, Latin America and Eastern Europe . Our study includes patients who were treated in 17 programmes from [8 ] 14 countries, and results should therefore be applicable to many other patients on ART in resource-limited countries. Of note, results were robust when restricting analyses to programmes from sub-Saharan Africa. However, we stress that the sites participating in the ART-LINC collaboration are not necessarily representative of all sites providing ART in these countries: they represent a sample of programmes with electronic medical record systems and access to CD4 counts and second-line regimens. [13 ] A substantial number of patients did not have a CD4 cell count recorded at the time of switching, and this could have introduced bias in the comparison of CD4 cell counts at switching in sites with and without viral load monitoring. This is unlikely, however: the baseline CD4 counts were similar in patients with missing counts in sites with and without viral load monitoring (data not shown). We did not examine clinical failure: not all sites systematically collect data on opportunistic infections and diagnostic capabilities and criteria vary between sites. Also, we had no information on adherence or drug-resistance, and data about reasons for switching were only available for some patients. In a programme of a faith-based organization in three countries in sub-Saharan Africa, immunological failure was the most common reason for switching, followed by virological failure. Clinical failures were rare . [14 ] We only considered switching of regimens, as recommended by WHO in case of treatment failure, and not substitutions of single
drugs or other changes. A recent study comparing Switzerland with the Khayelitsha and Gugulethu township programmes in South Africa
showed that changes to first-line regimens of any type occurred twice as often in Switzerland than in South Africa . The difference was, [7 ] however, explained by a higher rate of changes due to toxicity or patient wishes in Switzerland, while changes due to treatment failure were infrequent in both settings . In the present study, most of the patients with information on the reason for switching changed [7 ] regimens because of treatment failure, and results were similar when analyses were adjusted for differences in the first line regimens used in programmes with and without viral load monitoring.
Both in programmes with and without access to viral load monitoring the rates of switching were substantially higher than in the MSF programmes : the MSF programmes do not have access to viral load monitoring and the rate was 0.5 per 100 person-years. Rates were, [8 ] however, lower than in the programme in three African countries, which includes routine viral load monitoring in all sites: the rate of switching was 4.9 per 100 person-years . A multi-country survey by WHO found highly variable rates of switching to second-line [14 ] regimens . It seems unlikely that this variability is explained by differences in primary resistance to NRTIs or NNRTIs. At present [15 ] viral resistance is rare in most resource-limited settings, although important levels of resistance have been reported from Nigeria and North India . The availability of viral load monitoring and generally differences in clinical practice are more likely explanations: practice [16 ] varies across sites participating in the collaboration, even within the same country. For example, in township programmes in Cape Town, therapy is switched after two consecutive viral loads above 5,000 copies/ml in Khayelitsha whereas in Gugulethu the threshold is 1,000 copies/ml.
A low CD4 cell count when starting ART was the most important predictor of switching to a second-line regimen, in line with a previous study . Starting ART earlier might thus not only reduce the high mortality during the initial months of ART , , but [14 ] [7 10 17 ] also help preserve first-line regimens. The rate of switching was lower in more recent calendar years compared to the early years of the ART scale-up, again confirming previous findings . Of note, this was not explained by the increase in CD4 counts at the start of ART, [14 ] which was observed in more recent years : the effect was evident in analyses adjusted for baseline CD4 count, and might reflect a [10 ] change in practice associated with the substantial increase in patients starting ART since the early 2000s.
There is debate on the feasibility and cost-effectiveness of viral load monitoring in the context of scaling up of ART in resource-limited settings , , , . WHO stipulates that viral load monitoring is desirable, but not essential, for a public [18 19 20 20 -22 ] health approach to ART . According to a recent modelling study, routine viral load monitoring has only limited benefit on survival and [23 ] cost-effectiveness is poor . An analysis of mortality in the first year after starting ART showed similar survival in sites with and [20 ] without viral load monitoring , and preliminary results of a randomized trial led to similar conclusions . The results from empirical [17 ] [ 24 ] research are reassuring for sites without access to routine viral load monitoring but they are based on short-term follow-up and the effect of viral load monitoring on long-term outcomes is unclear at present. The higher CD4 cell counts at the time of switching in sites with, compared to sites without access to viral load monitoring indicate that treatment failure is detected earlier in programmes using viral load monitoring, and this might translate into better clinical outcomes in the long-term. 5 9 In conclusion, we found that in programmes with access to viral load monitoring patients tended to switch earlier and at higher CD4 cell counts than in sites without viral load monitoring. Future studies should examine what the consequences of earlier or later switching are for clinical outcomes. For example, the effect of switching based on virological failure in patients monitored virologically with switching based on immunological and clinical criteria could be compared in a randomised trial. Alternatively, this comparison could be mimicked in longitudinal, observational studies using causal modelling , . Finally, further research is required to determine the [25 26 ] optimal frequency of determining CD4 cell counts and of measuring viral load to maximize cost-effectiveness and optimize patient outcomes in different settings in lower income countries.
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Figure 1
Kaplan-Meier curves of the probability of switching to second-line antiretroviral regimens in 10 treatment programmes with and 7 programmes without virological monitoring. 
